Some people may envision the legalization of marijuana as an opportunity for someone like Philip Morris to start selling marijuana cigarettes. It is much closer to the truth to say that marijuana is showing potential for medical uses, and companies that are developing medical applications for the plant stand to gain in the marketplace.
The rush to get in on the marijuana craze has created hundreds of startups, but the odds are that many of these will fail. The winners so far are established companies that are adding marijuana to their focus. However, even some of these winners have seen drops in their stock prices lately. (See also: Want to Make Money in Marijuana? Read This First.)
We have selected four marijuana stocks that have the potential to make significant gains. These stocks were chosen based on their array of marijuana-related products. These products are either in use or awaiting approval by the Food and Drug Administration (FDA). All figures are current as of Dec. 4, 2017.
AbbVie Inc. (ABBV)
AbbVie is a pharmaceutical company that is ahead of the pack because it has a cannabis-based drug on the market. The FDA approved Marinol, which helps alleviate nausea or vomiting for chemotherapy patients. The drug also helps AIDS patients who have lost their desire to eat. It is important to note that Marinol is not AbbVie's flagship drug. In fact, it is not even the company's biggest seller.
AbbVie has reported increasing revenues in the past four years. In addition, its operating income has been increasing steadily. The company is benefiting from a host of useful drugs, including Marinol. Therefore, AbbVie is a way to play the marijuana trend without incurring 100% exposure to the plant. The risk of owning AbbVie is that it concentrates almost exclusively on U.S. markets, whereas most pharmaceutical companies market internationally. If the domestic market falters, the stock could see a drop in value. For investors, this risk is offset by the dividend, which is 2.95%. (For more, see: AbbVie Q3 Earnings Top, Revenues In Line, View Up.)
- Average Volume: 6,885,323
- Market Cap: $152.659 billion
- P/E Ratio (TTM): 23.52
- EPS (TTM): $4.07
- Dividend and Yield: $2.84 (2.95%)
The Scotts Miracle-Gro Company (SMG)
An interesting way to play the marijuana boom is Scotts Miracle-Gro. Known for its lawn and garden-care lines, the company is developing products for cannabis growers and also several pesticides for use on marijuana plants.
The stock had been in a sideways pattern since December 2016 and then dropped sharply from around $97 to nearly $83 per share in June 2017. It has been moving up again since then, touching all-time highs of over $102 per share. Revenues were down dramatically for the quarter ended April 1, 2017, but the company's income was up. Both income and revenues ticked down for the quarter ended July 1, 2017. Therefore, this could be a stock to watch instead of one to buy for now. (See also: Scotts Miracle-Gro Seeks High Profits in Marijuana.)
- Average Volume: 316,928
- Market Cap: $5.771 billion
- P/E Ratio (TTM): 27.07
- EPS (TTM): $3.71
- Dividend and Yield: $2.12 (2.15%)
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
This stock has seen some dramatic ups and downs over the past year. Hopes rise and fall for its marijuana-based drugs, which are in clinical trials. The company's lead drug anabasum, formerly known as resunab, which is designed to treat sclerosis, has had promising trials. The stock has tended to dip just before trial results are announced and then rally when the results are positive.
True to form, the stock soared on Oct. 19, 2017, in response to positive Phase 2 data showing anabasum's effectiveness in treating the inflammatory disease dermatomyositis, but the shares subsequently gave back the majority of those gains. The pessimism/optimism pattern will likely continue to play out as this drug is tested yet again. The company has negative operating income, and revenues are close to zero. Corbus is a company depending on the success of a single drug that could make or break it. (For more, see: Corbus Gets FDA Green Light for Phase 3 Study.)
- Average Volume: 711,620
- Market Cap: $419.707 million
- P/E Ratio (TTM): -12.75
- EPS (TTM): -$0.60
- Dividend and Yield: N/A (N/A)
INSYS Therapeurtics, Inc. (INSY)
Although this company markets many non-cannabis drugs, it is in the process of developing a synthetic cannabis drug to treat childhood epilepsy. INSYS is working on a spray technology to deliver pharmaceutical cannabinoids.
INSYS has had flat revenues for the past three years, but its operating income showed a sharp drop at the end of 2016, as the company spent more on research. Gross profit is higher than it was three years ago. The stock has fallen from $15 per share, and throughout October 2017, it fell sharply below prior support levels of $9 per share. Since then, the stock has been moving sideways at just above $5 per share. There has been more volatility than a prudent investor would usually want to see, but given that this is a biotech stock, the action is acceptable. (For more, see: Opioid Stocks Threatened by FDA Steps.)
- Average Volume: 712,734
- Market Cap: $392.992 million
- P/E Ratio (TTM): -24.31
- EPS (TTM): -$0.22
- Dividend and Yield: N/A (N/A)
The Bottom Line
As people sober up about the marijuana craze, the reality of using it in medicines and other products will set in. Like any other source for drugs, cannabis has positive prospects, but there are bound to be some failures. The drop in share prices for some marijuana stocks indicates that the companies need to deliver on the promise of medical cannabis soon.
It is best not to invest based on enthusiasm over marijuana and to keep a level head about actual results from drug trials. The pesticides angle is interesting, but such a product would have limited sales until marijuana is legalized nationwide. (For additional reading, check out: Top Marijuana Stocks That Pay Dividends.)